Article Text

PDF
Original article
Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery
  1. Rafael Cavalcante1,2,
  2. Yohei Sotomi3,
  3. Yaping Zeng1,
  4. Cheol Whan Lee4,
  5. Jung-Min Ahn4,
  6. Carlos Collet3,
  7. Erhan Tenekecioglu1,
  8. Pannipa Suwannasom1,3,
  9. Yoshinobu Onuma1,
  10. Seung-Jung Park4,
  11. Patrick W Serruys5
  1. 1Erasmus University Medical Center, Rotterdam, The Netherlands
  2. 2Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil
  3. 3Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  4. 4Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
  5. 5International Center for Circulatory Health, Imperial College London, London, UK
  1. Correspondence to Professor Patrick W Serruys, Department of Cardiology in the Cardiovascular Science Division of the NHLI within Imperial College of Science, Technology and Medicine, London, UK; Emeritus Professor of Medicine Erasmus University, Rotterdam, 3015 CE, The Netherlands; patrick.w.j.c.serruys{at}gmail.com

Abstract

Objective In patients with multivessel disease and proximal left anterior descending artery (LAD) involvement, the best revascularisation strategy is still unclear. We assess outcomes after coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) with drug-eluting stents in a pooled analysis of individual patient-level data of the SYNTAX and BEST randomised trials.

Design Proximal LAD involvement was defined by any lesion ≥ 50% diameter stenosis in the arterial segment starting from the left-main bifurcation up to (and including) the origin of the first major septal branch. The primary endpoint was the composite of all-cause death, myocardial infarction (MI) or stroke at 5 years of follow-up.

Results The present study population comprises 1166 patients of which 577 were randomised to PCI and 589 to CABG. Baseline characteristics were well balanced across study arms. The primary endpoint occurred in 94 (16.3%) patients in the PCI arm and in 68 (11.5%) patients in the CABG arm (HR 1.43; 95%CI 1.05 to 1.95; p=0.026). CABG was also associated with a significantly lower rate of cardiac death (p=0.007), MI (p<0.001), all-cause revascularisation (p<0.001) and major adverse cardiovascular and cerebrovascular events (all-cause death, MI, stroke, revascularisation) (p<0.001). The rates of all-cause mortality (p=0.06) and stroke (p=0.09) were not statistically different between the two groups. The overall study results for the primary outcome were consistent across several subgroups.

Conclusions In patients with multivessel disease with proximal LAD involvement, CABG is associated with lower rates of the safety composite endpoint of death, MI or stroke as compared with PCI with drug-eluting stents at 5 years of follow-up (number needed to treat=21).

Trial registration number PRECOMBAT clinicaltrials.gov NCT00997828; SYNTAX: clinicaltrials.gov identifier: NCT00114972 NCT00114972.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.